Imec, ’s werelds toonaangevende onderzoeks- en innovatiehub op het vlak van nano-elektronica en digitale technologie, staat mee aan de wieg van de eerste zorgrobot die gericht en persoonlijk kan interageren met rusthuisbewoners. De zorgrobot wordt vandaag gedemonstreerd bij de voorstelling van de resultaten van het imec.icon-project WONDER, een samenwerking tussen imec, de bedrijven Zora Robotics en Xetal en de woonzorgcentra WZC De Vijvers en WZC Weverbos.
Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces the successful outcome of a confirmatory bioequivalence study performed on a commercial batch of Myring™ produced at the Mithra CDMO. The study results reconfirm that Myring™ is bioequivalent to Nuvaring®, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA).
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today provided an update on key clinical and operational developments for the third quarter ended Sept. 30, 2017.
MindBytes BVBA, sister company of ISMS, and its subsidiary, MindLab Interactive AI Inc., (“MindBytes”) today announced it has initiated an oncology research & development program focused on empowering individuals with cancer and improving their lives. The Company plans to develop an interactive Cancer Patient Decision Aid (CADA) and an evidence-based serious game for breast cancer survivors. The Company is also developing patient preference elicitation tools to collect data that will be used to fine-tune CADA and create health economic models.
A broad range of metabolic and inflammatory diseases is associated with alterations in gut microbiota composition and metabolic potential. Until now, sequencing-based gut microbiota research has been describing such dysbiotic states in terms of proportional shifts in microbiome composition. However, when it comes to the bacterial content of your bowels and how it relates to your health, not only percentages matter, but also numbers count. That is at least one of the main messages of the latest research of Jeroen Raes (VIB-KU Leuven) and his team published today in the scientific journal Nature.
Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.
Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.
Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.
The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.
Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.
VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.
imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.
Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes.